Technical Analysis for RDUS - Radius Health, Inc.

Grade Last Price % Change Price Change
grade D 18.67 -0.69% -0.13
RDUS closed down 0.69 percent on Tuesday, March 19, 2019, on 65 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical RDUS trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Resistance Bearish 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 18 20 DMA Resistance Bearish -0.69%
Mar 18 Bollinger Band Squeeze Range Contraction -0.69%
Mar 18 Outside Day Range Expansion -0.69%
Mar 15 20 DMA Resistance Bearish 0.00%
Mar 15 Bollinger Band Squeeze Range Contraction 0.00%
Mar 15 Down 3 Days in a Row Weakness 0.00%
Mar 14 Fell Below 20 DMA Bearish -0.05%

Older signals for RDUS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Radius Health, Inc., a biopharmaceutical company, focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. Its lead product includes abaloparatide (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein, which is in Phase III clinical development for the treatment of osteoporosis. The company is also developing RAD1901, a selective estrogen receptor down-regulator/degrader for the treatment of breast cancer brain metastases, and vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator, which is in preclinical development stage for the treatment of weight loss due to cancer cachexia, muscle frailty and osteoporosis, and breast cancer. It has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai; Lonza Group Ltd.; and Charles River Laboratories, Inc. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biopharmaceutical Cancer Drugs Breast Cancer Endocrine System Hormones Osteoporosis Amines Treatment Of Breast Cancer Antiestrogens Eisai Selective Estrogen Receptor Modulators
Is RDUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.66
52 Week Low 12.81
Average Volume 544,290
200-Day Moving Average 20.341
50-Day Moving Average 18.2382
20-Day Moving Average 18.961
10-Day Moving Average 18.702
Average True Range 0.9143
ADX 16.13
+DI 20.2724
-DI 16.3504
Chandelier Exit (Long, 3 ATRs ) 17.8371
Chandelier Exit (Short, 3 ATRs ) 20.2929
Upper Bollinger Band 19.992
Lower Bollinger Band 17.93
Percent B (%b) 0.36
BandWidth 10.874954
MACD Line 0.1214
MACD Signal Line 0.2171
MACD Histogram -0.0957
Fundamentals Value
Market Cap 809.99 Million
Num Shares 43.4 Million
EPS -5.19
Price-to-Earnings (P/E) Ratio -3.60
Price-to-Sales 1353.51
Price-to-Book 6.40
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.71
Resistance 3 (R3) 19.73 19.40 19.53
Resistance 2 (R2) 19.40 19.14 19.39 19.47
Resistance 1 (R1) 19.04 18.98 18.88 19.02 19.42
Pivot Point 18.71 18.71 18.63 18.70 18.71
Support 1 (S1) 18.35 18.45 18.19 18.33 17.92
Support 2 (S2) 18.02 18.29 18.01 17.87
Support 3 (S3) 17.66 18.02 17.81
Support 4 (S4) 17.64